Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

600.50 -2.32 (-0.38%)
Streaming Delayed Price Updated: 12:48 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street ↗
Recent moves to the upside could be the beginning of a much larger bull run. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today ↗
Two key tailwinds appear to be lifting the stock today. 
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
News headline image
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug ↗
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
Via Investor's Business Daily
News headline image
Why These 3 Nasdaq Stocks Buckled Today ↗
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
News headline image
Analyst Expectations for Madrigal Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Slumping Today ↗
The biotech's shares briefly plunged following its 2023 Q1 earnings report. 
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/17 Morning Trading
Via Investor Brand Network
News headline image
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Biotechs That Might Get Bought Out in 2023 ↗
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
News headline image
Why Madrigal Pharmaceuticals Stock Gained 20% This Week ↗
Two key tailwinds fueled a surge in the biotech's share price this week. 
Via The Motley Fool
News headline image
2 Surging Healthcare Stocks That Are Still Worth Buying ↗
These two NASH drugmakers have a lot of room to run. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
News headline image
Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout ↗
Shares are closing in on a buy point after retaking their 50-day moving average. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
News headline image
5 Best Stocks to Buy in April ↗
These powerful trends should yield stellar returns for investors in April and beyond. 
Via The Motley Fool
News headline image
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run ↗
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
News headline image
Is Viking Therapeutics a Smart Buy on the Dip? ↗
The stock recently fell around 25% for reasons that had nothing to do with its lead program. 
Via The Motley Fool
News headline image
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle ↗
Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals. 
Via Investor's Business Daily
News headline image
1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030 ↗
This clinical-stage biopharma stock could harbor one of the best-selling drugs of all time. 
Via The Motley Fool
News headline image
3 Incredible Growth Stocks to Buy if the Market Dips ↗
These top growth stocks sport premium valuations for a very good reason. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks to Buy for January ↗
These healthcare stocks have a lot going for them in the new year. 
Via The Motley Fool
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
5 Most Expensive Health Care Stocks You Should Worry About ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.